{
    "symbol": "DNAY",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-14 23:28:11",
    "content": " Revenue during the period was driven in part by our highest number of quarterly placements of our BioXp 3250 instruments, strong growth in BioXp consumable kits, and biofoundry services, and increased partnership revenue related to our agreement with Pfizer. In addition to being a catalyst for growth, our biofoundry services team helps to expand our customer reach, build strong customer relationships and demonstrate the value of our BioXp instrumentation and the Codex DNA team\u2019s scientific expertise, which ultimately drives product sales."
}